Phase I Clinical Trial to Assess the Safety and Pharmacokinetic Profile of CKD-581 in Patients With Lymphoma or Multiple Myeloma Failed to Standard Therapy

Trial Profile

Phase I Clinical Trial to Assess the Safety and Pharmacokinetic Profile of CKD-581 in Patients With Lymphoma or Multiple Myeloma Failed to Standard Therapy

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs CKD 581 (Primary)
  • Indications Lymphoma; Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors Chong Kun Dang
  • Most Recent Events

    • 09 Mar 2018 Results published in the Investigational New Drugs
    • 03 Oct 2016 Status changed from recruiting to completed.
    • 31 Jul 2015 Planned End Date changed from 1 May 2013 to 1 Oct 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top